Michael A. Nauck

65.8k citations

382 papers · 47.2k indexed · 32 hit papers · h-index 97

Impact in

Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
Pharmacology top 0.02%
- Pharmacology and Obesity Treatment

Papers in

Endocrinology, Diabetes and Metabolism 331
- Diabetes Treatment and Management 311
- Diabetes Management and Research 146
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 23
Gastroenterology 20

Co-authors: Juris J. Meier Jens J. Holst Daniel J. Drucker W. Creutzfeldt John B. Buse David R. Matthews R. Ebert Ele Ferrannini
Journals: Diabetes Obesity and Metabolism (39 papers)Diabetologia (32 papers)Diabetes Care (29 papers)The Journal of Clinical Endocrinology & Metabolism (22 papers)Diabetes (21 papers)
Partner nations: Germany Denmark United States

In The Last Decade

Michael A. Nauck

374 papers receiving 45.6k citations

Hit Papers

15 papers align trajectories log scale

Incretin hormones and type 2 diabetes 2023 · 86 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Diabetologia
2023 American Heart Journal
2022 Cardiovascular Diabetology
2021 Diabetes Care
2021 Circulation
2021 Diabetes Obesity and Metabolism
2021 The Lancet Diabetes & Endocrinology
2020 Nature Reviews Endocrinology
2020 Molecular Metabolism
2019 The Lancet
2018 The Lancet
2018 Diabetes Obesity and Metabolism
2017 Circulation
2016 The Lancet Diabetes & Endocrinology
2016 New England Journal of Medicine
2015 Diabetes Obesity and Metabolism
2015 Diabetologia
2014 Diabetes Care
2012 The Lancet
2012 Diabetes Care
2011 Diabetes Care
2010 The Lancet
2008 Diabetes Care
2007 Diabetes Obesity and Metabolism
2006 The Lancet
1997 American Journal of Physiology-Endocrinology and Metabolism
1995 Diabetes
1995 Diabetes
1993 Journal of Clinical Investigation
1993 Diabetologia
1986 Diabetologia
1986 The Journal of Clinical Endocrinology & Metabolism

Peers

Countries citing papers authored by Michael A. Nauck

Since Specialization

Citations

This map shows the geographic impact of Michael A. Nauck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Nauck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Nauck more than expected).

Fields of papers citing papers by Michael A. Nauck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Nauck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Nauck. The network helps show where Michael A. Nauck may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael A. Nauck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael A. Nauck Line = papers co-authored together Michael A. Nauck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study Diabetes ·Daniel R. Quast, Cong Xie, Michelle J. Bound, Jacqueline Grivell, Seva Hatzinikolas, Karen L. Jones, Michael Horowitz, Christopher K. Rayner, Michael A. Nauck, Juris J. Meier, Anna C. Phillips, Tongzhi Wu	2025	1
2	Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes Diabetes Obesity and Metabolism ·Daniel R. Quast, Dara Lancaster, Cong Xie, Michelle J. Bound, Jacqueline Grivell, Karen L. Jones, Michael Horowitz, Juris J. Meier, Tongzhi Wu, Christopher K. Rayner, Michael A. Nauck	2024	1
3	Gut hormone co-agonists for the treatment of obesity: from bench to bedside Nature Metabolism ·Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp	2023	68
4	Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics American Heart Journal ·Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Michael A. Nauck, Steven E. Nissen, Naveed Sattar, Bernard Zinman, Sophia Zoungas, Jan Basile, Amy Bartee, Debra L. Miller, Hiroshi Nishiyama, Imre Pávó, Govinda J. Weerakkody, Russell J. Wiese, David A. D’Alessio Hit paper breakdown →	2023	120
5	Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens Diabetes Obesity and Metabolism ·Juan P. Frías, Michael A. Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Miličević, Shweta Urva, Axel Haupt, Deborah A. Robins	2020	171
6	The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists Diabetes Obesity and Metabolism ·Shweta Urva, Tamer Coşkun, Corina Loghin, Xuewei Cui, Emily Beebe, Libbey S. O′Farrell, Daniel A. Briere, Charles Benson, Michael A. Nauck, Axel Haupt	2020	92
7	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE , LEADER and SUSTAIN ‐6 cardiovascular outcomes trials Diabetes Obesity and Metabolism ·Anna R. Kahkoska, Milan S. Geybels, Klara R. Klein, Frederik Flindt Kreiner, Nikolaus Marx, Michael A. Nauck, Richard E. Pratley, Benjamin Ole Wolthers, John B. Buse	2020	52
8	COVID-19 and diabetes mellitus: from pathophysiology to clinical management Nature Reviews Endocrinology ·Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, Michael A. Nauck Hit paper breakdown →	2020	634
9	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art Molecular Metabolism ·Michael A. Nauck, Daniel R. Quast, Jakob Wefers, Juris J. Meier Hit paper breakdown →	2020	968
10	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes New England Journal of Medicine ·Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Lasse Steen Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse Hit paper breakdown →	2016	4935
11	Praxisempfehlungen DDG/DGIM : Therapie des Typ-2-Diabetes Diabetologie und Stoffwechsel ·R. Landgraf, Monika Kellerer, Eva-Maria Fach, Baptist Gallwitz, A. Hamann, Hans‐Georg Joost, H. H. Klein, D. Mueller‐Wieland, Michael A. Nauck, Heidi Reuter, Stefanie Schreiber, Erhard Siegel, S. Matthäei	2013	6
12	The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study Alimentary Pharmacology & Therapeutics ·Julie E. Stevens, Michael Horowitz, Carolyn F. Deacon, Michael A. Nauck, Christopher K. Rayner, Karen L. Jones	2012	37
13	Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study^1,2 Diabetic Medicine ·Robert E. Ratner, Michael A. Nauck, Christoph Kapitza, Veronica Asnaghi, Mark Boldrin, R. Balena	2010	37
14	Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β-cell area European Journal of Endocrinology ·Thomas Breuer, Bjoern A. Menge, Matthias Banasch, Waldemar Uhl, Andrea Tannapfel, Wolfgang E. Schmidt, Michael A. Nauck, Juris J. Meier	2010	13
15	Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits Postgraduate Medicine ·Michael A. Nauck, Michel Marre	2009	26
16	Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regulatory Peptides ·Helle Linnebjerg, Soomin Park, Prajakti A. Kothare, Michael Trautmann, Kenneth Mace, Mark Fineman, Ian R. Wilding, Michael A. Nauck, Michael Horowitz	2008	207
17	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Clinical Diabetology ·Michael A. Nauck, Sandra Johns, J. Northrup A. Festa, Robert G. Brodows, Michael Trautmann	2007	1
18	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects Diabetes ·Juris J. Meier, G. Kemmeries, Jens J. Holst, Michael A. Nauck	2005	114
19	Is glucagon-like peptide 1 an incretin hormone? Diabetologia ·Michael A. Nauck	1999	84
20	Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients Diabetic Medicine ·Michael A. Nauck, Irene T. Weber, I Bach, Sandy Richter, Cathrine Ørskov, Jens J. Holst, Wolff Schmiegel	1998	44

About Michael A. Nauck

Michael A. Nauck is a scholar working on Endocrinology, Diabetes and Metabolism, Gastroenterology, Surgery, Pharmacology and Molecular Biology, having authored 382 papers that have together received 47.2k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (311 papers), Metabolism, Diabetes, and Cancer (152 papers), Diabetes Management and Research (146 papers), Pancreatic function and diabetes (111 papers), Diet and metabolism studies (40 papers), Pharmacology and Obesity Treatment (39 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (23 papers) and Diabetes and associated disorders (19 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (39.1k citations), Pharmacology (7.1k citations), Surgery (17.8k citations), Endocrine and Autonomic Systems (2.3k citations) and Molecular Biology (17.3k citations). Michael A. Nauck has collaborated with scholars based in Germany, Denmark and United States. Frequent co-authors include Juris J. Meier, Jens J. Holst, Daniel J. Drucker, W. Creutzfeldt, John B. Buse, David R. Matthews, R. Ebert, Ele Ferrannini, Michaëla Diamant and Richard M. Bergenstal. Their work appears in journals such as Diabetes Obesity and Metabolism, Diabetologia, Diabetes Care, The Journal of Clinical Endocrinology & Metabolism and Diabetes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact